Sustained antidepressant action of the N‑methyl‑D‑aspartate receptor antagonist MK‑801 in a chronic unpredictable mild stress model

Yang,Bang‑Kun; Qin,Jun; Nie,Ying; Chen,Jin‑Cao

doi:10.3892/etm.2018.6876

Sustained antidepressant action of the N‑methyl‑D‑aspartate receptor antagonist MK‑801 in a chronic unpredictable mild stress model

Authors:
- Bang‑Kun Yang
- Jun Qin
- Ying Nie
- Jin‑Cao Chen
View Affiliations

Affiliations: Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442600, P.R. China, Department of Children's Medical Center, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442600, P.R. China
Published online on: October 18, 2018 https://doi.org/10.3892/etm.2018.6876
Pages: 5376-5383

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

(5S,10R)‑5‑methyl‑10,11‑dihydro‑5H‑dibenzo(A,D)cyclohepten‑5,10‑imine hydrogen maleate (MK‑801) is an N‑methyl‑D‑aspartate non‑competitive antagonist that possesses useful biological properties, including anticonvulsant and anesthetic activities. Studies have indicated the rapid antidepressant effects of MK‑801 in animal models. However, there are no reports concerning a sustained antidepressant effect in the chronic unpredictable mild stress (CUMS) model. Furthermore, the antidepressant mechanism remains unclear. The aim of the present study was to examine the effects of MK‑801 (0.1 mg/kg) and rapastinel (10 mg/kg) on depression‑like behavior in CUMS mice and measure the protein expression of brain‑derived neurotrophic factor (BDNF), α‑amino‑3‑hydroxy‑5‑methyl‑4‑isoxazolepropionic acid receptor (GluA1) and phosphorylated mammalian target of rapamycin (p‑mTOR). In the tail suspension and forced swim tests, MK‑801 significantly attenuated the increased immobility time in CUMS mice compared with the vehicle group. In the sucrose preference test, a single‑dose injection of MK‑801 significantly ameliorated the decreased sucrose preference in CUMS mice compared with the vehicle group. Western blot analyses indicated that MK‑801 significantly attenuated the decreased BDNF, GluA1 and p‑mTOR protein levels in the medial prefrontal cortex (mPFC), dentate gyrus (DG) and CA3 of the hippocampi of CUMS mice. Conversely, this compound had no effect on increased BDNF, GluA1 and p‑mTOR protein levels in the nucleus accumbens of CUMS mice. Therefore, the present study revealed the sustained antidepressant effects of MK‑801 in the CUMS model. Furthermore, synaptogenesis and neuronal regeneration in the prelimbic regions of mPFC, DG and CA3 of the hippocampus may be implicated as mechanisms that promote a sustained antidepressant response.

View Figures

View References

1	Monteggia LM and Zarate CA Jr: Antidepressant actions of ketamine: From molecular mechanisms to clinical practice. Curr Opin Neurobiol. 30:139–143. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hashimoto K: Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci. 16:7796–7801. 2015. View Article : Google Scholar : PubMed/NCBI
3	Chaki S and Fukumoto K: Potential of glutamate-based drug discovery for next generation antidepressants. Pharmaceuticals (Basel). 8:590–606. 2015. View Article : Google Scholar : PubMed/NCBI
4	Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S and Kasper S: European group for the study of resistant depression (GSRD)-where have we gone so far: Review of clinical and genetic findings. Eur Neuropsychopharmacol. 22:453–468. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN and Iversen LL: The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA. 83:7104–7108. 1986. View Article : Google Scholar : PubMed/NCBI
6	Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA and Moskal JR: GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 38:729–742. 2013. View Article : Google Scholar : PubMed/NCBI
7	Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET and Monteggia LM: NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 475:91–95. 2011. View Article : Google Scholar : PubMed/NCBI
8	Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, et al: NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 533:481–486. 2016. View Article : Google Scholar : PubMed/NCBI
9	Yang B, Ren Q, Ma M, Chen QX and Hashimoto K: Antidepressant effects of (+)-MK-801 and (−)-MK-801 in the social defeat stress model. Int J Neuropsychopharmacol. 19(pii): pyw0802016. View Article : Google Scholar : PubMed/NCBI
10	Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM and Khan MA: The development of rapastinel (Formerly GLYX-13); A rapid acting and long lasting antidepressant. Curr Neuropharmacol. 15:47–56. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lu Y, Wang C, Xue Z, Li C, Zhang J, Zhao X, Liu A, Wang Q and Zhou W: PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int J Neuropsychopharmacol. 18(pii): pyu1102014.PubMed/NCBI
12	Yang B, Zhang JC, Han M, Yao W, Yang C, Ren Q, Ma M, Chen QX and Hashimoto K: Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl). 233:3647–3657. 2016. View Article : Google Scholar : PubMed/NCBI
13	Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR and Burch RM; GLYX-13 Clinical Study Group, . Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 21:140–149. 2015. View Article : Google Scholar : PubMed/NCBI
14	Duman RS and Aghajanian GK: Synaptic dysfunction in depression: Potential therapeutic targets. Science. 338:68–72. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lepack AE, Fuchikami M, Dwyer JM, Banasr M and Duman RS: BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 18:pyu0332014. View Article : Google Scholar : PubMed/NCBI
16	Ohgi Y, Futamura T and Hashimoto K: Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med. 15:206–221. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner KM, Zhang JC, Yang C, Yao W, Dong C, et al: Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci USA. 113:E1944–E1952. 2016. View Article : Google Scholar : PubMed/NCBI
18	Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C and Hashimoto K: R-ketamine: A rapid-acting and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 5:e6322015. View Article : Google Scholar : PubMed/NCBI
19	Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M and Hashimoto K: Comparison of ketamine, 7,8-dihydroxyflavone and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl). 232:4325–4335. 2015. View Article : Google Scholar : PubMed/NCBI
20	Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G and Duman RS: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 329:959–964. 2010. View Article : Google Scholar : PubMed/NCBI
21	Miller OH, Yang L, Wang CC, Hargroder EA, Zhang Y, Delpire E and Hall BJ: GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife. 3:e035812014. View Article : Google Scholar : PubMed/NCBI
22	Krystal JH, Sanacora G and Duman RS: Rapid-acting glutamergic antidepressants: The path to ketamine and beyond. Biol Psychiatry. 73:1133–1141. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lodge D and Mercier MS: Ketamine and phencyclidine: The good, the bad and the unexpected. Br J Pharmacol. 172:4254–4276. 2015. View Article : Google Scholar : PubMed/NCBI
24	Haj-Mirzaian A, Kordjazy N, Haj-Mirzaian A, Ostadhadi S, Ghasemi M, Amiri S, Faizi M and Dehpour A: Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests. Psychopharmacology (Berl). 232:3551–3561. 2015. View Article : Google Scholar : PubMed/NCBI
25	Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagic A, Luckenbaugh DA, Drevets WC and Theodore WH: 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry. 62:1258–1264. 2007. View Article : Google Scholar : PubMed/NCBI
26	Luykx JJ, Laban KG, van den Heuvel MP, Boks MP, Mandl RC, Kahn RS and Bakker SC: Region and state specific glutamate downregulation in major depressive disorder: A meta-analysis of (1)H-MRS findings. Neurosci Biobehav Rev. 36:198–205. 2012. View Article : Google Scholar : PubMed/NCBI
27	Feyissa AM, Chandran A, Stockmeier CA and Karolewicz B: Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 33:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
28	Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M and Landen JW: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 28:631–637. 2008. View Article : Google Scholar : PubMed/NCBI
29	Duman RS, Aghajanian GK, Sanacora G and Krystal JH: Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med. 22:238–249. 2016. View Article : Google Scholar : PubMed/NCBI
30	Ren Q, Ma M, Yang C, Zhang JC, Yao W and Hashimoto K: BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Transl Psychiatry. 5:e6662015. View Article : Google Scholar : PubMed/NCBI
31	Yang C, Shirayama Y, Zhang JC, Ren Q and Hashimoto K: Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol. 18:pyu1212015. View Article : Google Scholar : PubMed/NCBI
32	Hashimoto K: Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression. Prog Neurobiol. 100:15–29. 2013. View Article : Google Scholar : PubMed/NCBI
33	Yang B, Yang C, Ren Q, Zhang JC, Chen QX, Shirayama Y and Hashimoto K: Regional differences in the expression of brain-derived neurotrophic factor (BDNF) pro-peptide, proBDNF and preproBDNF in the brain confer stress resilience. Eur Arch Psychiatry Clin Neurosci. 266:765–769. 2016. View Article : Google Scholar : PubMed/NCBI
34	Hashimoto K, Malchow B, Falkai P and Schmitt A: Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Neurosci. 263:367–377. 2013. View Article : Google Scholar
35	Shirayama Y, Yang C, Zhang JC, Ren Q, Yao W and Hashimoto K: Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol. 25:2449–2458. 2015. View Article : Google Scholar : PubMed/NCBI